Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

VXRT - Vaxart Inc Stock Price, Fair Value and News

$0.42-0.03 (-6.67%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

VXRT Price Action

Last 7 days

-6.7%

Last 30 days

23.5%

Last 90 days

-40.8%

Trailing 12 Months

-42.5%

VXRT RSI Chart

AugSepOctNovDec2025FebMarAprMay01020304050607080

VXRT Valuation

Market Cap

95.7M

Price/Earnings (Trailing)

-1.43

Price/Sales (Trailing)

3.34

EV/EBITDA

-1.22

Price/Free Cashflow

-2.11

VXRT Price/Sales (Trailing)

202220232024202505001K1.5K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VXRT Fundamentals

VXRT Revenue

Revenue (TTM)

28.7M

Rev. Growth (Yr)

367.95%

Rev. Growth (Qtr)

207.82%

20102012201420162018202020222024010M20M30M40M50M60M70M

VXRT Earnings

Earnings (TTM)

-66.9M

Earnings Growth (Yr)

31.02%

Earnings Growth (Qtr)

14.88%

20102012201420162018202020222024-100M-80M-60M-40M-20M0

VXRT Profitability

Operating Margin

-53.66%

EBT Margin

-232.36%

Return on Equity

-113.62%

Return on Assets

-40.24%

Free Cashflow Yield

-47.34%

VXRT Investor Care

Shares Dilution (1Y)

31.11%

Revenue Breakdown

As of: Dec 31, 2024
201820202022202402M4M6M8M10M12M
Government Contract
ProductValuePercent
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20248.9M13.9M16.8M28.7M
2023697.0K2.1M4.2M7.4M
2022471.0K359.0K159.0K107.0K
20211.6M1.2M1.2M892.0K
20207.4M7.8M7.6M4.0M
20198.1M7.5M7.7M9.9M
20185.0M3.8M3.2M4.2M
20175.3M3.2M6.6M5.8M
2016011.5M9.4M7.4M
201523.5M8.4M13.6M0
201469.5M68.7M53.6M38.5M
201324.9M33.6M44.4M52.5M
201214.0M10.9M11.2M19.5M
201130.4M29.3M18.1M16.1M
2010018.7M26.8M35.0M
200900010.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
 CEO
 WEBSITEhttps://vaxart.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES164

Vaxart Inc Frequently Asked Questions

What is the ticker symbol for Vaxart Inc? What does VXRT stand for in stocks?

VXRT is the stock ticker symbol of Vaxart Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxart Inc (VXRT)?

As of Mon May 05 2025, market cap of Vaxart Inc is 95.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VXRT stock?

You can check VXRT's fair value in chart for subscribers.

Is Vaxart Inc a good stock to buy?

The fair value guage provides a quick view whether VXRT is over valued or under valued. Whether Vaxart Inc is cheap or expensive depends on the assumptions which impact Vaxart Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VXRT.

What is Vaxart Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 05 2025, VXRT's PE ratio (Price to Earnings) is -1.43 and Price to Sales (PS) ratio is 3.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VXRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vaxart Inc's stock?

In the past 10 years, Vaxart Inc has provided -0.332 (multiply by 100 for percentage) rate of return.